Skip to content
lifestyle.clientim.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Medicus Pharma Ltd
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
September 10, 2026
Medicus Pharma Focuses on Precision Oncology and CD228V
September 8, 2026
Medicus Pharma Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Medicus Pharma Appoints Dr. Faisal Mehmud as Chief Executive Officer of Antev Limited, United Kingdom
August 3, 2026
Medicus Pharma Receives UAE Department of Health (DOH) Authorization to proceed with Novel Prospective Genomics Guided Precision Medicine Study Evaluating Teverelix® in Women with Endometriosis
July 31, 2026
Medicus Pharma Receives FDA “Study May Proceed” Letter for NDA-Enabling Registrational SkinJect® Study in Patients with Gorlin Syndrome
July 27, 2026
Medicus Pharma Advances SkinJect® into Registrational Development for Gorlin Syndrome
June 3, 2026
Medicus Pharma Announces $22 Million Non-Dilutive Financing
May 28, 2026
Medicus Pharma Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
Medicus Pharma Announces Results from Pre-Specified Expanded Phase 2 SKNJCT-003 Data Analysis Demonstrating Positive Dose-Response
May 6, 2026
1
2
3
Next Page
→